deltatrials
Completed PHASE1 INTERVENTIONAL 5-arm NCT02361723

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation, and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors

Sponsor: BeiGene

Conditions For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment
Interventions BGB-290
Updated 16 times since 2017 Last updated: Dec 24, 2024 Started: Jul 3, 2014 Primary completion: Sep 3, 2019 Completion: Sep 3, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment and is currently completed. BeiGene leads this study, which shows 16 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – present · 17 months · monthly snapshot

Change History

16 versions recorded

  1. Jan 2025 — Present [monthly]

    Completed PHASE1

  2. Nov 2024 — Jan 2025 [monthly]

    Completed PHASE1

  3. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 11 earlier versions

  1. May 2020 — Jan 2021 [monthly]

    Completed PHASE1

  2. Feb 2020 — May 2020 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  3. Dec 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  4. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1

  5. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1

  6. Aug 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Unknown Status → Active Not Recruiting

  7. Jun 2019 — Aug 2019 [monthly]

    Unknown Status PHASE1

    Status: Recruiting → Unknown Status

  8. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE1

  9. Jun 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  10. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE1

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeiGene
Data source: BeiGene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations